Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459771 | 0.92 | NPY2R (0.52) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5462081 | 0.87 | NPY2R (0.62) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5457840 | 0.86 | NAMPT (0.62) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5453449 | 0.86 | NPC1 (0.56) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5458483 | 0.83 | MEN1 (0.59) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5473462 | 0.82 | DGAT1 (0.53) | — | |
| SCHEMBL5459036 | 0.80 | RAB9A (0.57) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5464907 | 0.80 | NAMPT (0.62) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL34466018 | 0.79 | MEN1 (0.58) | NPY2RNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5455943 | 0.78 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | NPY2R 2089/4885NPC1 1089/4885RAB9A 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.